Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease

Current Treatment Options in Gastroenterology

Volumn 10, Issue 3, 2007, Pages 185-194

  Zisman, Timothy L ^b   Cohen, Russell D ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ALPHA4 INTEGRIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MLN 02; NATALIZUMAB; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBODY PRODUCTION; BONE PAIN; CATARACT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE UTILIZATION; HUMAN; IMMUNOGENICITY; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE REACTION; LOADING DRUG DOSE; MAINTENANCE THERAPY; ONSET AGE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRODUCTIVITY; QUALITY OF LIFE; REMISSION; REVIEW; RISK REDUCTION; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; ULCERATIVE COLITIS; WOUND HEALING IMPAIRMENT;

EID: 34250615928     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0012-4     Document Type: Review

References (50)

1. Loftus EV, Jr: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
2. Hay AR, Hay JW: Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992, 14:318-327.
3. Cohen RD, Larson LR, Roth JM, et al.: The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000, 95:524-530.
4. Feagan BG, Vreeland MG, Larson LR, Bala MV: Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000, 95:1955-1960.
5. Bernstein CN, Papineau N, Zajaczkowski J, et al.: Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000, 95:677-683.
6. Hay JW, Hay AR: Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992, 14:309-317.
7. Bassi A, Dodd S, Williamson P, Bodger K: Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004, 53:1471-1478.
8. Blomqvist P, Ekbom A: Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997, 32:1134-1139.
9. Feagan BC, Bala M, Yan S, et al.: Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005, 39:390-395.
10. Lichtenstein GR, Yan S, Bala M, Hanauer S: Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91-96.
11. Guyatt G, Mitchell A, Irvine EJ, et al.: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
12. Irvine EJ, Feagan B, Rochon J, et al.: Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-296.
13. Ware JE, Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
14. Drossman DA, Leserman J, Li ZM, et al.: The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991, 53:701-712.
15. Cohen RD: The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002, 16:1603-1609.
16. Hanauer SB, Cohen RD, Becker RV, 3rd, et al.: Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998, 20:1009-1028.
17. Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337:1029-1035.
18. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
19. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
20. Remicade. In Physicians' Desk Reference, vol 61 Montvale, NJ: Thompson PDR; 2007:971-979.
21. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
22. Staff ME, Cohen HE, eds. Drug Topics Red Book Update. Montvale, NJ: Medical Economics Co.; January 2007.
23. Rubenstein JH, Chong RY, Cohen RD: Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002, 35:151-156.
24. Lichtenstein GR, Yan S, Bala M, et al.: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
25. Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
26. Sandborn WJ, Lichtenstein GR, Colombel JF, et al.: Infliximab therapy reduces hospitalizations in ulcerative colitis patients [abstract]. Am J Gastroenterol 2005, 100:A847.
27. Lichtenstein GR, Bala M, Han C, et al.: Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8:237-243.
28. Feagan BG, Yan S, Bala M, et al.: The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003, 98:2232-2238.
29. van Balkom BP, Schoon EJ, Stockbrugger RW, et al.: Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease. Aliment Pharmacol Ther 2002, 16:1101-1107.
30. Feagan BG, Rutgeerts PJ, Hanauer SB, et al.: Infliximab therapy improves health related quality of life in ulcerative colitis patients [abstract]. Am J Gastroenterol 2005, 100:A792.
31. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
32. Parsi MA, Achkar JP, Richardson S, et al.: Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002, 123:707-713.
33. Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333. Quiz 591.
34. Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
35. Papadakis KA, Shaye OA, Vasiliauskas EA, et al.: Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75-79.
36. Sandborn WJ, Hanauer S, Loftus EV, Jr, et al.: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004, 99:1984-1989.
37. Schreiber S, Rutgeerts P, Fedorak RN, et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
38. Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1) [abstract]. Gastroenterology 2006, 130:A107-A108.
39. Schreiber S, Khaliq-Kareemi M, Lawrance I: Certolizumab pegol, a humanised anti-TNF pegylated FAb′ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECiSE) [abstract]. Gut 2005, 54:A82.
40. Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn's disease. N Engl J Med 2003, 348:24-32.
41. Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
42. Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
43. Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699-705.
44. Feagan BG, Enns R, Colombel JF, et al.: Natalizumab improves the health related quality of life (HRQOL) in Crohn's disease patients [abstract]. Am J Gastroenterol 2005, 100:A842.
45. Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
46. van Deventer SJ, Tami JA, Wedel MK: A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004, 53:1646-1651.
47. Miner PB, Jr, Wedel MK, Xia S, Baker BF: Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006, 23:1403-1413.
48. Miner P, Wedel M, Bane B, Bradley J: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004, 19:281-286.
49. Yacyshyn BR, Chey WY, Goff J, et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002, 51:30-36.
50. Korzenik JR, Dieckgraefe BK, Valentine JF, et al.: Sargramostim for active Crohn's disease. N Engl J Med 2005, 352:2193-2201.